Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025


Acquisition adds taletrectinib, a next-generation,...

Related Keywords

United States ,Japan ,New York ,China ,Shanghai ,Decheng ,Guangdong ,San Francisco ,California ,Cayman ,00 ,Cayman Islands ,Daiichi Sankyo ,Junyuan Jerry Wang ,Innovent Biologics ,Nuvation Bio ,Walkers Cayman ,Morrison Foerster Llp ,Exchange Commission ,Morrison Foerster ,Drug Administration ,China National Medical Products Administration ,Davis Polk Wardwell ,Anheart Therapeutics Ltd ,Nuvation Bio Inc ,Medivation Inc ,Newg Lab ,Anheart Therapeutics ,David Hung ,Chief Executive Officer ,Min Cui ,Managing Director ,Decheng Capital ,Non Voting Convertible Preferred Stock ,Nuvation Bio Stockholder Approval ,Nuvation Bio Stockholder ,Breakthrough Therapy Designations ,National Medical Products Administration ,Priority Review Designation ,New Drug Applications ,Fangda Partners ,Heart Therapeutics ,Priority Review Designations ,Greater China ,Nippon Kayaku ,